ASTRA:CRYPTOCAPMarket Cap ASTRA, $ Analysis

AstraZeneca trades at $189.9, just above the calculated support of $189.35 and below its 20‑day SMA of $201.53, indicating limited upside in the near term. The RSI of 38 suggests the stock is approaching oversold territory, while a bearish MACD histogram reinforces short‑term downside pressure. Despite these technical headwinds, the company posts a robust 4.1% revenue growth, 81.7% gross margin, and a 22.8% ROE, underscoring strong underlying profitability. The forward PE of 31.8 and a current PE of 29 sit above the industry average of 26, and a DCF‑derived fair value of $66.8 signals that the market price is significantly overvalued. Dividend sustainability appears solid, with a 1.68% yield, a 48% payout ratio, and ample free cash flow to cover distributions. The low beta of 0.44 points to limited systematic risk, though 30‑day volatility of 29% and a max drawdown of 16.4% highlight heightened price swings. Analyst sentiment is bullish, reflected in a “strong_buy” consensus and a median price target of $219, implying expectations of a recovery toward the 52‑week high of $212.71. The company’s global footprint and diversified therapeutic portfolio mitigate regulatory and geographic risks, while its strong balance sheet (net debt $23B) supports ongoing R&D and dividend commitments. Overall, the stock sits at a crossroads where technical weakness meets solid fundamentals and an optimistic long‑term outlook.
Investors should weigh the near‑term technical downside against the company’s resilient earnings, attractive dividend, and favorable long‑term growth catalysts.